TL;DR: Trestle Biotherapeutics is a Y Combinator Winter 2021 startup Bioengineered kidneys for patients with kidney failure, currently active with a team of 2.
Bioengineered kidneys for patients with kidney failure
Last verified:
We are developing an implantable therapeutic tissue that will be surgically delivered to patients suffering from end stage renal disease. Upon implantation, this tissue will supplement the patient's renal function, eliminating their dependency on dialysis and improving their disease status. This has the potential to not only get these patients off dialysis - a significant impact for them and their families - but to greatly extend the time required before kidney transplantation is essential.
Built by LemStudio
Yes. Trestle Biotherapeutics was funded by Y Combinator in the Winter 2021 batch. Bioengineered kidneys for patients with kidney failure
We are developing an implantable therapeutic tissue that will be surgically delivered to patients suffering from end stage renal disease. Upon implantation, this tissue will supplement the patient's renal function, eliminating their dependency on dialysis and improving their disease status. This has the potential to n…
Trestle Biotherapeutics was part of Y Combinator's Winter 2021 batch.
Trestle Biotherapeutics has a team of 2 people according to Y Combinator's directory.
Trestle Biotherapeutics is currently listed as Active with a team of 2 in Y Combinator's directory.
Loading interactive view…